SI2686002T1 - A method for reducing influenza-like symptoms associated with intramuscular delivery of interferon by the rapid titration-enhancing regimen - Google Patents

A method for reducing influenza-like symptoms associated with intramuscular delivery of interferon by the rapid titration-enhancing regimen Download PDF

Info

Publication number
SI2686002T1
SI2686002T1 SI201231281T SI201231281T SI2686002T1 SI 2686002 T1 SI2686002 T1 SI 2686002T1 SI 201231281 T SI201231281 T SI 201231281T SI 201231281 T SI201231281 T SI 201231281T SI 2686002 T1 SI2686002 T1 SI 2686002T1
Authority
SI
Slovenia
Prior art keywords
interferon
patient
use according
week
needle
Prior art date
Application number
SI201231281T
Other languages
English (en)
Slovenian (sl)
Inventor
Aaron Deykin
Original Assignee
Biogen Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc. filed Critical Biogen Ma Inc.
Publication of SI2686002T1 publication Critical patent/SI2686002T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
SI201231281T 2011-03-15 2012-03-15 A method for reducing influenza-like symptoms associated with intramuscular delivery of interferon by the rapid titration-enhancing regimen SI2686002T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161452807P 2011-03-15 2011-03-15
US201161476930P 2011-04-19 2011-04-19
EP12719487.6A EP2686002B1 (en) 2011-03-15 2012-03-15 Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
PCT/US2012/029201 WO2012125809A1 (en) 2011-03-15 2012-03-15 Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen

Publications (1)

Publication Number Publication Date
SI2686002T1 true SI2686002T1 (en) 2018-06-29

Family

ID=46045072

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201231281T SI2686002T1 (en) 2011-03-15 2012-03-15 A method for reducing influenza-like symptoms associated with intramuscular delivery of interferon by the rapid titration-enhancing regimen

Country Status (25)

Country Link
US (6) US9198955B2 (https=)
EP (1) EP2686002B1 (https=)
JP (2) JP6279905B2 (https=)
KR (1) KR102050339B1 (https=)
CN (1) CN103702680A (https=)
AU (1) AU2012229104B2 (https=)
BR (1) BR112013023609A8 (https=)
CA (1) CA2846786C (https=)
CY (1) CY1120176T1 (https=)
DK (1) DK2686002T3 (https=)
EA (1) EA028448B1 (https=)
ES (1) ES2666850T3 (https=)
HR (1) HRP20180621T1 (https=)
HU (1) HUE036931T2 (https=)
IL (1) IL228425A (https=)
LT (1) LT2686002T (https=)
MX (1) MX359947B (https=)
PL (1) PL2686002T3 (https=)
PT (1) PT2686002T (https=)
RS (1) RS57175B1 (https=)
SG (1) SG193446A1 (https=)
SI (1) SI2686002T1 (https=)
SM (1) SMT201800221T1 (https=)
WO (1) WO2012125809A1 (https=)
ZA (1) ZA201306933B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012229104B2 (en) * 2011-03-15 2017-03-16 Biogen Ma Inc. Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
EP3092305B1 (en) * 2014-01-09 2023-08-02 Kyushu University, National University Corporation Method of producing microglial cells
US11266344B2 (en) 2016-09-21 2022-03-08 Samsung Electronics Co., Ltd. Method for measuring skin condition and electronic device therefor
CN116391233A (zh) * 2020-09-30 2023-07-04 皇家飞利浦有限公司 用于执行剂量滴定的方法和系统

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456748A (en) 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
EP0070906B1 (en) 1981-02-04 1986-10-15 Juridical Foundation Japanese Foundation For Cancer Research Human interferon-beta gene
US4695543A (en) 1982-03-23 1987-09-22 Bristol-Myers Company Alpha Interferon GX-1
CA1302320C (en) 1984-06-11 1992-06-02 Hideo Niwa Expression of human cromosomal interferon-_ in animal cells
US5231176A (en) 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
FI90990C (fi) 1984-12-18 1994-04-25 Boehringer Ingelheim Int Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi
EP0205404B1 (en) 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid interferons
US5641656A (en) 1993-10-22 1997-06-24 University Of Connecticut Nucleic acids encoding avian interferon (IFN) proteins and recombinant methods using them
JP4878664B2 (ja) * 1996-12-24 2012-02-15 バイオジェン・アイデック・エムエイ・インコーポレイテッド 安定な液体インターフェロン処方物
JP2001104482A (ja) * 1999-10-07 2001-04-17 Terumo Corp ２室型プレフィルドシリンジ
WO2004069302A2 (en) * 2003-01-30 2004-08-19 Becton, Dickinson And Company Holder with safety shield for a drug delivery device
UA92146C2 (ru) * 2004-06-01 2010-10-11 Эйрэс Трейдинг С.А. Стабилизированная жидкая композиция, которая содержит интерферон
US20060089593A1 (en) * 2004-10-26 2006-04-27 Sergio Landau Needle-free injection device for individual users
EP1923085A1 (en) * 2006-11-17 2008-05-21 Sanofi-Aventis Deutschland GmbH Dosing and drive mechanism for drug delivery device
AU2007333959A1 (en) 2006-12-18 2008-06-26 Altus Pharmaceuticals Inc. Human growth hormone formulations
US9044378B2 (en) * 2007-05-31 2015-06-02 Safety Syringes, Inc. Anti-needle stick safety device or system for use with drugs requiring reconstitution
JP5549048B2 (ja) * 2007-08-16 2014-07-16 味の素株式会社 薬剤バイアルとプレフィルドシリンジの接続構造
AU2010263058A1 (en) * 2009-06-18 2012-01-12 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
AU2012229104B2 (en) * 2011-03-15 2017-03-16 Biogen Ma Inc. Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen

Also Published As

Publication number Publication date
US10500254B2 (en) 2019-12-10
US20170360890A1 (en) 2017-12-21
SG193446A1 (en) 2013-10-30
US9198955B2 (en) 2015-12-01
EA028448B1 (ru) 2017-11-30
US20250276042A1 (en) 2025-09-04
KR102050339B1 (ko) 2019-11-29
BR112013023609A2 (pt) 2016-12-06
IL228425A (en) 2017-08-31
PT2686002T (pt) 2018-04-23
CA2846786C (en) 2022-05-17
IL228425A0 (en) 2013-12-31
BR112013023609A8 (pt) 2018-04-03
CA2846786A1 (en) 2012-09-20
KR20140038383A (ko) 2014-03-28
CY1120176T1 (el) 2018-12-12
LT2686002T (lt) 2018-05-10
US20200046804A1 (en) 2020-02-13
NZ616536A (en) 2015-10-30
JP6279905B2 (ja) 2018-02-14
WO2012125809A1 (en) 2012-09-20
AU2012229104A1 (en) 2013-10-03
HRP20180621T1 (hr) 2018-07-27
NZ712273A (en) 2016-09-30
RS57175B1 (sr) 2018-07-31
US20160101157A1 (en) 2016-04-14
SMT201800221T1 (it) 2018-07-17
PL2686002T3 (pl) 2018-10-31
MX359947B (es) 2018-10-17
ES2666850T3 (es) 2018-05-08
MX2013010507A (es) 2014-04-30
EA201301024A1 (ru) 2014-03-31
DK2686002T3 (en) 2018-04-30
JP6522069B2 (ja) 2019-05-29
ZA201306933B (en) 2016-07-27
AU2012229104B2 (en) 2017-03-16
JP2014508174A (ja) 2014-04-03
HUE036931T2 (hu) 2018-08-28
EP2686002B1 (en) 2018-01-24
US20220280610A1 (en) 2022-09-08
JP2018030847A (ja) 2018-03-01
US20120237479A1 (en) 2012-09-20
CN103702680A (zh) 2014-04-02
EP2686002A1 (en) 2014-01-22

Similar Documents

Publication Publication Date Title
Zhang et al. Just how prevalent are peptide therapeutic products? A critical review
NZ599558A (en) Dosing regimen associated with long-acting injectable paliperidone esters
MY149419A (en) Dosing and drive mechanism for drug delivery device
MX2009005098A (es) Mecanismo dosificador y accionador para dispositivos de descarga de farmacos.
NZ599309A (en) Palm activated drug delivery device
JP2013509435A5 (https=)
MY148971A (en) Improvements in and relating to drive mechanisms suitable for use in drug delivery devices
HRP20231151T1 (hr) Režimi za doziranje spojeva iz klase ehinokandina
HRP20210624T1 (hr) Režimi doziranja amisulprida za liječenje mučnine i povraćanja
CO6361944A2 (es) Combinacion de una insulina y un agonista de glp-1
SI2625199T1 (en) Procedures for treating psoriasis using IL-17 antagonists
JP2018510898A5 (https=)
IL159662A0 (en) Administration appliance comprising a dosage device
HRP20201027T1 (hr) Režim doziranja za propuštene doze injektibilnih estera paliperidona s produljenim djelovanjem
SI2686002T1 (en) A method for reducing influenza-like symptoms associated with intramuscular delivery of interferon by the rapid titration-enhancing regimen
MX2022008236A (es) Metodos para administrar altas concentraciones de oxido nitrico.
WO2012052853A3 (en) Oral dosing device for administration of medication
JP2018510894A5 (https=)
HRP20201388T1 (hr) Režimi i postupci liječenja multiple skleroze uporabom ofatumumaba
JP2019511506A5 (https=)
AR088204A1 (es) Medicamentos para el tratamiento de la rinitis alergica que comprenden un antagonista de pgd2 y un antagonista de histamina
MX2023010313A (es) Formulación y métodos de gliburida de baja sorción.
JP2016515137A5 (https=)
RU2013150024A (ru) Способы контроля и лечения хронической боли с применением hcg
MX2018000257A (es) Dispositivo de suministro de un solo uso que tiene caracteristicas de seguridad.